Neurons in mice spit out monomeric tau when electrically stimulated, hinting that neural activity may help drive the spread of pathological forms of tau in the brain.
A Phase 2 trial suggests that the drug PBT2 is generally safe for Huntington’s patients. The drug's sponsor says it may have improved cognition, though experts remain unconvinced.
Live imaging of the mouse brain offers a rare view of α-synuclein dynamics at presynaptic terminals, and raises questions about which form of the protein triggers synaptic dysfunction.
Proteins that interact with the Parkinson’s risk gene LRRK2 point to protein trafficking and degradation as causes of pathogenesis.
Once considered a nuclear homebody, TDP-43 ventures out to accompany mRNAs down axons to nerve terminals where the transcripts can be turned into protein.
Government, industry, and advocacy together will provide nearly $130 million for the identification of surrogate markers and targets.
Mutant FUS meddles with RNA splicing and DNA damage repair in transgenic mice that succumb to disease.
The antidepressant citalopram reduces agitation in Alzheimer’s patients, but caused abnormal heart rhythms at the tested dose.
Superficial siderosis, a leakage of blood matter onto the outer surface of the cerebral cortex, may be linked to AD and other dementias.
Aggressively treating high blood pressure and cholesterol in older adults with diabetes does not prevent cognitive decline, and results in more brain shrinkage.
A new grant opportunity will fund projects aimed at understanding the similarities and differences between biomarkers of Alzheimer’s and Parkinson’s diseases.
Already linked to Alzheimer’s and other neurodegenerative diseases, a TREM2 variant now shows up on the ALS radar, too.
The FDA has stopped the personal genome sequencing company 23andMe from selling health assessments, saying its tests need validation. What do Alzheimer scientists think?
Detecting oligomers in the cerebrospinal fluid is no easy feat. The latest test is among the most sensitive yet, but is it useful?
A new initiative in the U.K. will fund research into potential treatments for dementia and neurodegeneration.